Several groups are comparing Bionano with standard cytogenetic assays like karyotyping, FISH, or array CGH for blood cancer or genetic disease testing.
Test volumes, revenues per test and costs per test improved during the quarter, company executives said.
NeoGenomics will pay $125 million in cash and distribute 1 million shares of its stock to Genoptix, a clinical oncology lab, as part of the deal.
The companion diagnostic test identifies patients taking the Novartis drug Tasigna who are candidates for treatment-free remission monitoring.
The merger, which was previously scuttled and later revived with Rosetta shareholder approval, was due to close on May 27.
Upon completion of the transaction, Rosetta will become a privately held subsidiary of Genoptix and its shares will cease to trade on the Nasdaq.
The deal comes as the firms try — for the second time — to close a merger that had previously failed to gain necessary approval from Rosetta shareholders.
Genoptix's $9 million bid for Rosetta comes just days after the companies' first merger agreement failed to secure shareholder approval.
Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.
The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.
Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.
In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.